Research And Development Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Iron(Iii) Oxide-Sucrose Complex (B03ac02) as Part of an Open-House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Albendazole (P02ca03) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Trientine (A16ax12) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Ritonavir (J05ae03) as Part of a So-Called Open House Model.

Open House Drug Discount Agreements Colecalciferol, Rx, Prescription Products, Atc A11cc05

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Teriflunomide (L04aa31) as Part of a So-Called Open House Model.

Completion of a Non-exclusive Framework Contract Surveying Services in the Open House Procedure of the Southern Bavaria Branch, Published in 2023

Dynamic Procurement System for Insurance Services

Procurement of Air-Conditioner

Open House Drug Discount Agreements Botulinum Toxin Type A, Finished Drug Name: Xeomin(R), Atc M03ax21